Fondazione IRCCS Istituto Nazionale Dei Tumori — Sponsor Intelligence | 26 EU Trials

Filter these 26 trials by condition, phase, country and more.

Open in Search →

26 Registered trials

16 Recruiting

5 Completed trials

1 Countries active

40 Unique IMPs

100% Results reported

Phase II

Phase III: 2 Phase II: 21 Phase IV: 1 Phase I (FiH): 2

100%

5 of 5 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Mantle cell lymphoma refractory 1 Adult T-cell lymphoma/leukaemia 1 Brain stem glioma 1 Mantle cell lymphoma recurrent 1 Triple negative breast cancer 1 Bladder cancer 1 Pseudomyxoma peritonei 1 Adult T-cell lymphoma/leukaemia refractory 1 Mantle cell lymphoma 1 Ovarian cancer 1 Adult T-cell lymphoma/leukaemia recurrent 1 Clear cell renal cell carcinoma 1

Top IMPs

PEMBROLIZUMAB 5 ACETYLSALICYLIC ACID 3 CARBOPLATIN 3 CISPLATIN 3 DEXAMETHASONE PHOSPHATE 2 DURVALUMAB 2 ETOPOSIDE 2 KETOROLAC TROMETAMOL 2 METFORMIN HYDROCHLORIDE 2 PACLITAXEL 2 ATEZOLIZUMAB 1 BREXUCABTAGENE AUTOLEUCEL 1

All trials

26 total

Targeting inflammation to reduce 90-day and 1-year postoperative severe morbidity in patients with unfavorable inflammatory profile undergoi… Not authorised

2024-515333-14-00 Phase III 1 country ACETYLSALICYLIC ACID; KETOROLAC TROMETAMOL; SODIUM CHLORIDE
Activity of Pembrolizumab plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma (REPRINT trial) Pending

2024-511587-93-00 Phase II 1 country PEMBROLIZUMAB
Targeting inflammation to reduce 90-day and 1-year postoperative severe morbidity in patients with unfavorable inflammatory profile undergoi… Pending

2024-515333-14-03 Phase II 1 country ACETYLSALICYLIC ACID; KETOROLAC TROMETAMOL
Bladder Preservation with Sacituzumab Govitecan + Zimberelimab for MuscleInvasive Bladder cancer in cisplatin-unfit and unwilling for cystec… Pending

2024-516943-14-01 Phase II 1 country SACITUZUMAB GOVITECAN; ZIMBERELIMAB
Phase II study of Cemiplimab before and after standard chemoradiotherapy for patients with locally advanced cervical carcinoma. CADILLACC TR… Pending

2025-521839-36-00 Phase II 1 country CEMIPLIMAB; CISPLATIN
Metronomic neoadjuvant capecitabine and cyclophosphamide in huge (PCI>28) Pseudomyxoma peritonei (PMP) patients candidates to cytoreductive … Recruiting

2024-514329-42-00 Phase II 1 country CAPECITABINE; CYCLOPHOSPHAMIDE MONOHYDRATE
A study of niraparib in combination with abemaciclib for late line treatment of ovarian cancer: a single center, open label, single arm, pha… Recruiting

2022-501910-79-01 Phase I (FiH) 1 country
A randomized trial of multi-factorial primary prevention in high risk subjects candidate to a lung cancer early detection CT program Recruiting

2024-513660-26-00 Phase II 1 country ACETYLSALICYLIC ACID; CYTISINE
Akynzeo as antiemetic treatment in patients with endometrial cancer treated with taxane - platinum combination chemotherapy. NOEME study. Recruiting

2023-504150-35-00 Phase IV 1 country ATEZOLIZUMAB; CARBOPLATIN; DEXAMETHASONE PHOSPHATE; DOSTARLIMAB; DURVALUMAB; PAC…
Phase II, open label, single arm study of PembrolizumAb combiNeD with cisplatin or carbOplatin and etoposide in treatment naïve advanced meR… Recruiting

2022-500988-12-00 Phase II 1 country CARBOPLATIN; CISPLATIN; ETOPOSIDE; PEMBROLIZUMAB
Circulating microRNAs to choose the IO strategy in PD-L1≥50% NSCLC patients: the Ark clinical trial Recruiting

2022-502253-34-00 Phase II 1 country CARBOPLATIN; CISPLATIN; PACLITAXEL; PEMBROLIZUMAB; PEMETREXED
Temozolomide and irinotecan consolidation in patients with MGMT silenced, microsatellite stable colorectal cancer with persistence of minima… Recruiting

2024-515681-14-00 Phase II 1 country
Randomized study to protect from radiation iatrogenic hypothyroidism patients with medulloblastoma (any stage, any biological risk) and pedi… Recruiting

2024-512642-42-00 Phase III 1 country LEVOTHYROXINE
Multicenter phase II study of preoperative chemoradiotherapy with CApecitabine plus Temozolomide in patients with MGMT silenced and microsat… Recruiting

2024-513931-26-00 Phase II 1 country
Personalized therapy of metastatic thyroid cancer: biological characterization and optimization with 124I PET dosimetry Recruiting

2024-516273-80-00 Phase II 1 country SODIUM IODIDE (131I)
Phase 1b/2 trial of 5-fluorouracil, leucovorin, irinotecan in combination with temozolomide (FLIRT) and bevacizumab for the first-line treat… Recruiting

2024-515580-64-00 Phase I (FiH) 1 country
Phase II study of adjuvant pressurized intraperitoneal aerosol chemotherapy (PIPAC) for the prevention of peritoneal metastases after curati… Recruiting

2024-513376-17-00 Phase II 1 country FLUOROURACIL; LEVOLEUCOVORIN; OXALIPLATIN
A Phase II trial aiming to assess the safety and activity of the combination of cabozantinib plus lanreotide in gastroenteropancreatic (GEP)… Recruiting

2024-516612-16-00 Phase II 1 country
Randomized Controlled Trial comparing two groups of Patients with High-Risk, Localized Soft Tissue Sarcoma of the Extremity: the first one r… Recruiting

2024-517858-10-00 Phase II 1 country PEMBROLIZUMAB
Cabozantinib plus Durvalumab in patients with advanced and chemotherapy-treated bladder carcinoma, of urothelial and non-urothelial histolog… Recruiting

2023-509821-29-00 Phase II 1 country CABOZANTINIB; DURVALUMAB
Safety of Lanreotide 120 mg ATG in combination with Metformin in patients with progressive advanced Well-differentiated gastro-intestinal (G… Recruiting

2024-513200-34-00 Phase II 1 country LANREOTIDE; METFORMIN HYDROCHLORIDE
Pilot phase II study of Selinexor in combination with Ifosfamide, Etoposide and Dexamethasone (SIDE) in patients with relapsed or refractory… Ended

2024-513295-18-00 Phase II 1 country DEXAMETHASONE PHOSPHATE; ETOPOSIDE; IFOSFAMIDE; SELINEXOR
Targeting triple negative BREAst cancer metabolism with a combination of chemotherapy and a diet mimicking FASTing plus/minus metformin in t… Ended

2023-508920-37-00 Phase II 1 country METFORMIN HYDROCHLORIDE
A phase 2 open label study of caBozantinib in patients with advanced or unresectable Renal cEll cArcinoma pretreated with one immunochecKPOi… Ended

2024-514058-59-00 Phase II 1 country

Showing 1–24 of 26 trials

← All sponsors A–Z